Protein A Resin Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Protein A Resin market size was estimated at USD 1.12 billion in 2023 and is projected to reach USD 1.89 billion in 2030 at a CAGR of 7.8% during the forecast period 2024-2030.

The demand for monoclonal antibodies has surged significantly during the COVID-19 pandemic due to their critical role in diagnosing and treating the virus. This increase has driven manufacturers to accelerate the development and production of monoclonal antibodies to meet the growing patient needs. Protein A resins, essential for the purification of these antibodies, have consequently seen heightened demand. The urgency for COVID-19 vaccines has also contributed to this trend, alongside increased investments in the biopharmaceutical industry aimed at combating the pandemic.

However, the COVID-19 pandemic also disrupted global supply chains, impacting the availability of raw materials and manufacturing components, which negatively affected the protein A resins market. Research and development activities faced delays due to resource reallocation towards COVID-19-related projects, compounding these challenges. Despite these disruptions, the rising prevalence of chronic diseases, such as cancer, has sustained the demand for monoclonal antibodies, bolstering the need for efficient purification processes using protein A resins.

Monoclonal antibodies are pivotal in modern drug development, particularly for oncology, autoimmune, and infectious diseases, necessitating robust purification methods. This has led to increased demand for protein A resins. For instance, a 2023 report by the Society of Biological Engineering Journal highlighted the surge in protein A resin demand due to the biopharmaceutical industry's need for efficient purification methods.

The high costs associated with protein A resins remain a challenge for market growth. However, manufacturers are investing in research and development to innovate and develop advanced protein A chromatography resins or alternatives. Strategies like mergers, acquisitions, collaborations, and product launches are employed to expand regional presence and diversify product offerings. Notable examples include Purolite Life Sciences' launch of next-generation chromatography resins in 2021 and Thermo Fisher Scientific's collaboration with Newomics to develop a novel LC-MS platform.

Delvens Industry Expert's Standpoint

The pharmaceutical and biopharmaceutical companies are anticipated to dominate the protein A resin market, primarily due to their extensive use of proteins in drug discovery and development. Protein analysis is crucial for target identification, efficacy and toxicity biomarker identification, and understanding drug mechanisms, which is fueling market growth amidst numerous ongoing drug development projects globally. Government funding and technological advancements in analytical instruments further drive this segment's growth. Increasing life science R&D expenditure, drug discovery progress, and the adoption of chromatography are key drivers. For instance, Merck's investment in an advanced research centre in Germany and Otsuka Pharmaceutical's Osaka Research Centre underline the industry's commitment to antibody research, thereby boosting protein A resin demand.

Additionally, strategic agreements and expansions, such as Purolite's extended agreement with Repiligen Corporation and Ecolab Inc.'s new biologics resin manufacturing facility, highlight the industry's response to the growing demand. The competitive and fragmented nature of the protein A resin market sees major players continually introducing innovative products and forming partnerships to maintain a market edge. This dynamic environment, coupled with ongoing R&D, underscores the sector's robust growth trajectory, making protein A resins indispensable in pharmaceutical and biopharmaceutical applications.

Market Portfolio

Key Findings

• On the basis of Product Type, the agarose-based protein A segment held a significant share of the market in 2023. This resin is extensively utilized in the biopharmaceutical and biotechnology industries due to its versatility, efficiency, and reliability. Agarose-based protein A resin offers a high binding capacity for antibodies, facilitating the purification of large quantities of proteins in a single run. Its stability across a wide range of pH and salt conditions allows for adaptability to various purification protocols, ensuring robust and reliable results. Additionally, agarose-based protein A resin can be regenerated and reused multiple times without significant performance loss, making it a cost-effective option for repeated purification cycles.

• On the basis of Application, Antibody purification emerged as the largest segment in 2023. Protein A resin, engineered for capturing and purifying antibodies with remarkable specificity and efficiency, plays a crucial role in producing high-quality, therapeutically effective monoclonal antibodies. It achieves exceptional purity levels by removing contaminants and aggregates, resulting in antibodies with minimal impurities. The resin's rapid binding kinetics and high capacity enable efficient antibody capture, streamlining the purification process. Furthermore, it is well-suited for large-scale production, maintaining performance consistency even in high-volume purification processes.

• On the basis of End User, the pharmaceutical company's segment is poised for substantial growth during the forecast period, driven by the increasing utilization of Protein A resin. This trend highlights the resin's critical role in the purification processes of biopharmaceutical products. Protein A resin is highly valued for its efficiency in capturing and purifying antibodies and other therapeutic proteins, making it an essential tool for pharmaceutical companies. Its adoption aligns with the industry's dedication to producing high-quality biologics, monoclonal antibodies, and other therapeutic agents. As the demand for innovative medical treatments continues to rise, the reliance on Protein A resin is expected to grow, reinforcing its significance in the pharmaceutical sector.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America led the global market with approximately 38% share in 2023, driven by significant investments in monoclonal antibodies, a robust biopharmaceutical industry, and strong R&D capabilities. The U.S. held the major share, supported by stringent FDA regulations ensuring safety and quality.

Regional Analysis

• North America emerged as the largest region in 2023. Pharmaceutical companies, research institutions, and government organizations in North America are channelling substantial investments into research and development activities, spurring the development of new biopharmaceuticals and driving the demand for Protein A Resin. Additionally, the growing biosimilars market, driven by cost-effectiveness and healthcare affordability concerns, has created a surge in demand for Protein A Resin. The presence of numerous Contract Manufacturing Organizations (CMOs) specializing in biologics production further contributes to this demand, as these CMOs rely heavily on advanced purification technologies.

• The Asia-Pacific region is anticipated to experience significant growth during the forecast period. The rising demand for biologics and monoclonal antibodies has led to an increased need for Protein A Resin as a crucial purification tool. This growth is driven by the increasing prevalence of chronic diseases and the demand for innovative therapies. Several countries in the Asia-Pacific region are actively expanding their biomanufacturing capabilities and infrastructure. Investments in advanced bioprocessing facilities and the development of biotech hubs are fostering a favourable environment for the Protein A Resin market's expansion.

Competitive Landscape

• Abcam PLC.
• Agilent Technologies
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• EMD Millipore
• Expedeon Ltd
• GE Healthcare
• GenScript Biotech Corp.
• Merck Millipore
• Novasep Holdings SAS
• PerkinElmer, Inc.
• Purolite Life Sciences
• Repligen Corp.
• Thermo Fisher Scientific Inc.
• Tosoh Bioscience
• Agarose Bead Technologies
• Axplora
• Kaneka Corporation
• JSR Life Science

Recent Developments

• In February 2024, Purolite, now part of Ecolab, collaborated with Repligen Corporation to announce the commercial release of Praesto CH1, a new 70 μm agarose-based affinity resin tailored for purifying specialized monoclonal antibodies, including bispecifics and recombinant antibody fragments.

• In January 2024, Dutch Oxitope and Norwegian Arxx announced their merger to establish Calluna Pharma Inc., focusing on the development of monoclonal antibody therapies targeting inflammatory and fibrotic diseases. The newly formed company successfully raised USD 80.4 million (EUR 75 million) in Series A financing to advance its clinical-stage lead program, CAL101. CAL101 is a monoclonal antibody designed to neutralize the bioactivity of S100A4 and is currently undergoing Phase 1 trials for indications related to fibrosis and inflammation.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Protein A Resin Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope